China Biologic Products Holdings, Inc

(NASDAQ:CBPO)

Latest On China Biologic Products Holdings, Inc (CBPO):

Date/Time Type Description Signal Details
2021-04-20 21:13 ESTNewsChina Biologic Products gains on Nasdaq delisting notice for take privateN/A
2021-03-30 03:26 ESTNewsChina Biologic Products EPS beats by $0.22N/A
2020-12-13 03:27 ESTFinancialsCompany financials have been released.Neutral
2020-11-28 03:25 ESTFinancialsCompany financials have been released.Neutral
2020-11-27 11:29 ESTAnalyst RatingThe Analyst Target Price has increased from $101.78 to $102.78.Neutral
2020-11-27 03:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 20:09 ESTNewsChina Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call TranscriptN/A
2020-11-25 19:52 ESTNewsChina Biologic Products EPS beats by $0.12N/A
2020-11-25 19:51 ESTNewsChina Biologic Products Holdings, Inc. 2020 Q3 - Results - Earnings Call PresentationN/A
2020-11-25 11:33 ESTEarnings EstimateAn EPS average of $1.35 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-19 13:36 ESTNewsChina Biologic inks merger agreement for going private transactionN/A
2020-11-15 11:33 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 17:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-24 00:24 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 08:27 ESTFinancialsCompany financials have been released.Neutral
2020-08-19 08:28 ESTNewsUpdate on China Biologic Products Q2 earningsN/A
2020-08-19 08:28 ESTNewsChina Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call TranscriptN/A
2020-08-19 00:21 ESTFinancialsCompany financials have been released.Neutral
2020-08-18 04:05 ESTNewsChina Biologic Products EPS misses by $0.17N/A
2020-08-10 12:22 ESTAnalyst RatingThe Analyst Target Price has increased from $96.22 to $101.78.Neutral
2020-07-31 00:28 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:32 ESTFinancialsCompany financials have been released.Neutral
2020-07-10 08:21 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 08:17 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 04:22 ESTEarnings EstimateAn EPS average of $1.21 is estimated for the quarter ending on September 30, 2020.Sell
2020-05-31 16:49 ESTFinancialsCompany financials have been released.Neutral
2020-05-24 00:18 ESTFinancialsCompany financials have been released.Neutral
2020-05-22 06:57 ESTNewsChina Biologic Products EPS beats by $0.18N/A
2020-05-22 06:56 ESTNewsChina Biologic Products Holdings, Inc. 2020 Q1 - Results - Earnings Call PresentationN/A
2020-05-22 06:56 ESTNewsChina Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call TranscriptN/A
2020-05-03 08:24 ESTFinancialsCompany financials have been released.Neutral
2020-04-11 06:24 ESTNewsChina Biologic Products reports Q4 resultsN/A
2020-04-07 04:19 ESTAnalyst RatingThe Analyst Target Price has increased from $93.62 to $96.22.Neutral
2020-04-07 00:27 ESTFinancialsCompany financials have been released.Neutral
2020-04-01 20:16 ESTEarnings EstimateAn EPS average of $1.39 is estimated for the quarter ending on June 30, 2020.Buy
2020-04-01 20:16 ESTEarnings EstimateAn EPS average of $5.09 is estimated for the 2021 year.Buy
2020-03-24 04:17 ESTAnalyst RatingThe Analyst Target Price has increased from $88.28 to $93.62.Neutral
2020-03-14 00:21 ESTFinancialsCompany financials have been released.Neutral
2020-03-13 23:32 ESTNewsChina Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call TranscriptN/A
2020-03-13 23:32 ESTNewsChina Biologic Products Holdings, Inc. 2019 Q4 - Results - Earnings Call PresentationN/A
2020-03-11 04:18 ESTAnalyst RatingThe Analyst Target Price has increased from $88.22 to $88.28.Neutral
2020-02-28 23:20 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 03:22 ESTFinancialsCompany financials have been released.Neutral
2020-02-21 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-02-06 23:18 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 23:19 ESTFinancialsCompany financials have been released.Neutral
2020-01-28 03:23 ESTEarningsEarnings have been released on March 7, 2019, with $0.89 earnings per share.Buy
2020-01-27 23:16 ESTFinancialsCompany financials have been released.Neutral
2020-01-15 23:17 ESTFinancialsCompany financials have been released.Neutral
2020-01-06 03:13 ESTAnalyst RatingThe Analyst Target Price has decreased from $91.3 to $88.22.Sell

About China Biologic Products Holdings, Inc (CBPO):

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.

CBPO Quotes by TradingView

See Advanced Chart

General

  • Name China Biologic Products Holdings, Inc
  • Symbol CBPO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 2,246
  • Fiscal Year EndDecember
  • IPO Date2008-01-29
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.chinabiologic.com
View More

Valuation

  • Trailing PE 32.91
  • Forward PE 21.19
  • Price/Sales (Trailing 12 Mt.) 9.15
  • Price/Book (Most Recent Quarter) 2.4
  • Enterprise Value Revenue 6.67
  • Enterprise Value EBITDA 15.19
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate $0.69
  • Profit Margin 27%
  • Operating Margin 35%
  • Return on Assets 6%
  • Return on Equity 9%
  • Revenue 514.4 million
  • Earnings Per Share $3.57
  • Revenue Per Share $13.35
  • Gross Profit 329.08 million
  • Quarterly Earnings Growth 1.8%
View More

Highlights

  • Market Capitalization 4.56 billion
  • EBITDA 208.59 million
  • PEG Ratio 1.53
  • Analyst Target Price $102.78
  • Book Value Per Share $48.63
View More

Share Statistics

  • Shares Outstanding 38.79 million
  • Shares Float 13.05 million
  • % Held by Insiders 4559%
  • % Held by Institutions 50.29%
  • Shares Short 904687
  • Shares Short Prior Month 978972
  • Short Ratio 4.02
  • Short % of Float 4%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 0.42
  • 52 Week High $120.01
  • 52 Week Low $97.91
  • 50 Day Moving Average 118.36
  • 200 Day Moving Average 115.79
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

China Biologic Products Holdings, Inc (CBPO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

China Biologic Products Holdings, Inc (CBPO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-24$138.54 million$1.39$1.288.59%
2020-06-302020-08-17$N/A$1.11$1.28-13.28%
2020-03-312020-05-20$162.59 million$1.56$1.3813.04%
2019-12-312020-03-12$102.16 million$0.53$0.70-24.29%
2019-09-302019-11-13$136.11 million$1.40$0.8859.09%
2019-06-302019-08-05$135.7 million$1.24$1.0320.39%
2019-03-312019-05-10$129.78 million$1.11$0.9912.69%
2018-12-312019-03-06$114.93 million$0.76$0.6320.63%
2018-09-302018-11-01$119.11 million$0.96$0.97-0.72%
2018-06-302018-08-03$120.38 million$1.17$1.24-5.26%
2018-03-312018-05-04$112.46 million$1.21$1.28-5.47%
2017-12-312018-02-28$90.12 million$0.90$0.874.05%
2017-09-302017-11-01$99.56 million$1.38$1.1916.46%
2017-06-302017-08-02$89.28 million$1.35$1.304.25%
2017-03-312017-05-03$91.45 million$1.32$1.246.45%
2016-12-312017-02-23$77.63 million$0.95$0.8413.1%
2016-09-302016-11-02$86.53 million$1.22$1.0516.19%
2016-06-302016-08-04$91.42 million$1.26$1.168.62%
2016-03-312016-05-04$85.59 million$1.09
2015-12-312016-02-25$68.29 million$0.59$0.557.27%
2015-09-302015-11-03$78.75 million$0.82$0.811.23%
2015-06-302015-08-05$79.07 million$0.99$0.8713.79%
2015-03-312015-05-06$70.35 million$0.87$0.843.57%
2014-12-312015-03-04$57.99 million$0.48$0.51-5.88%
2014-09-302014-11-05$68.92 million$0.76$0.6418.75%
2014-06-302014-08-05$60.07 million$0.79$0.6717.91%
2014-03-312014-05-07$56.27 million$0.69
2013-12-312014-03-12$42.59 million$0.32$0.38-15.79%
2013-09-302013-11-05$53.15 million$0.56$0.4233.33%
2013-06-302013-08-06$53.58 million$0.62$0.4829.17%
2013-03-312013-05-08$54.03 million$0.59$0.4628.26%
2012-12-312013-03-13$34 million$0.21$0.1816.67%
2012-09-302012-11-09$53.12 million$0.50
2012-06-302012-08-10$50.47 million$0.46
2012-03-312012-05-08$47.23 million$0.44
2011-12-312012-03-12$35.65 million$0.29
2011-09-302011-11-07$41.3 million-$0.37
2011-06-302011-08-09$41.67 million$0.28
2011-03-312011-05-09$34.47 million$0.23$0.26-11.54%
2010-12-312011-03-31$35.68 million-$0.19$0.39-148.72%
2010-09-302010-11-15$36 million$0.53$0.3265.63%
2010-06-302010-08-16$40.91 million$0.49$0.3636.11%
2010-03-312010-05-17$27.1 million$0.41$0.2846.43%
2009-12-312010-03-23$37.63 million-$0.17$0.24-170.83%
2009-09-302009-11-16$27.04 million-$0.29
2009-06-302009-08-17$33.18 million$0.32
2009-03-312009-05-18$21.15 million$0.20
2008-09-302008-11-12$13.8 million$0.21
2008-06-302008-09-03$11.93 million$0.09
2008-03-312008-03-31$7.85 million$0.10
2007-09-302007-09-30$8.94 million$0.11
2007-06-302007-06-30$8.83 million$0.25

China Biologic Products Holdings, Inc (CBPO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

China Biologic Products Holdings, Inc (CBPO) Chart:

China Biologic Products Holdings, Inc (CBPO) News:

Below you will find a list of latest news for China Biologic Products Holdings, Inc (CBPO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

China Biologic Products Holdings, Inc (CBPO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

China Biologic Products Holdings, Inc (CBPO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465920077738/0001104659-20-077738-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000031506618001126/0000315066-18-001126-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000085874418000012/0000858744-18-000012-index.htm
2018-02-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000089843218000186/0000898432-18-000186-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000089843219000205/0000898432-19-000205-index.htm
2019-09-27SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000089843219001206/0000898432-19-001206-index.htm
2019-11-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000089843219001297/0000898432-19-001297-index.htm
2020-03-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000089843220000377/0000898432-20-000377-index.htm
2020-04-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000089843220000490/0000898432-20-000490-index.htm
2020-09-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000089843220000780/0000898432-20-000780-index.htm
2020-10-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000089843220000832/0000898432-20-000832-index.htm
2018-09-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000090266418003339/0000902664-18-003339-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000090266419001102/0000902664-19-001102-index.htm
2019-09-19SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000090266419003770/0000902664-19-003770-index.htm
2020-01-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000090266420000488/0000902664-20-000488-index.htm
2020-05-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000090266420002022/0000902664-20-002022-index.htm
2020-09-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000090266420003366/0000902664-20-003366-index.htm
2020-10-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000090266420003758/0000902664-20-003758-index.htm
2018-12-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000095010318014719/0000950103-18-014719-index.htm
2019-01-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000095010319000310/0000950103-19-000310-index.htm
2019-02-04SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000095010319001572/0000950103-19-001572-index.htm
2019-03-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000095010319003298/0000950103-19-003298-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000107333018000006/0001073330-18-000006-index.htm
2017-10-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000108887517000059/0001088875-17-000059-index.htm
2019-10-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465919054506/0001104659-19-054506-index.htm
2019-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465919063391/0001104659-19-063391-index.htm
2019-11-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465919064932/0001104659-19-064932-index.htm
2020-01-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920006462/0001104659-20-006462-index.htm
2020-01-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920006484/0001104659-20-006484-index.htm
2020-01-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920006492/0001104659-20-006492-index.htm
2020-02-19SC 13E3/AGoing private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1369868/000110465920022796/0001104659-20-022796-index.htm
2020-03-1220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/0001104659-20-032518-index.htm
2020-03-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465920032579/0001104659-20-032579-index.htm
2020-03-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920036400/0001104659-20-036400-index.htm
2020-03-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920036457/0001104659-20-036457-index.htm
2020-03-30SC 13E3/AGoing private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1369868/000110465920039960/0001104659-20-039960-index.htm
2020-04-08SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920044714/0001104659-20-044714-index.htm
2020-04-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920045389/0001104659-20-045389-index.htm
2020-04-24SC 13E3/AGoing private transaction by certain issuershttps://www.sec.gov/Archives/edgar/data/1369868/000110465920050713/0001104659-20-050713-index.htm
2020-05-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920055013/0001104659-20-055013-index.htm
2020-05-05SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920056574/0001104659-20-056574-index.htm
2020-05-07SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920057789/0001104659-20-057789-index.htm
2020-05-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1369868/000110465920058842/0001104659-20-058842-index.htm
2020-05-11SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920059145/0001104659-20-059145-index.htm
2020-05-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465920064316/0001104659-20-064316-index.htm
2020-06-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465920077738/0001104659-20-077738-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000110465920096148/0001104659-20-096148-index.htm
2020-09-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920105926/0001104659-20-105926-index.htm
2020-09-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920105937/0001104659-20-105937-index.htm
2020-09-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920105941/0001104659-20-105941-index.htm
2020-09-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920107498/0001104659-20-107498-index.htm
2020-10-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920118751/0001104659-20-118751-index.htm
2020-10-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920118753/0001104659-20-118753-index.htm
2020-10-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920118756/0001104659-20-118756-index.htm
2020-10-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000110465920119144/0001104659-20-119144-index.htm
2019-09-30SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114036119017530/0001140361-19-017530-index.htm
2020-01-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114036120001388/0001140361-20-001388-index.htm
2020-09-18SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114036120020820/0001140361-20-020820-index.htm
2017-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369868/000114420417039925/0001144204-17-039925-index.htm
2017-08-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420417040005/0001144204-17-040005-index.htm
2017-08-038-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1369868/000114420417040336/0001144204-17-040336-index.htm
2017-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420417051728/0001144204-17-051728-index.htm
2017-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420417052328/0001144204-17-052328-index.htm
2017-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420417055529/0001144204-17-055529-index.htm
2017-12-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420417063829/0001144204-17-063829-index.htm
2017-12-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420417065699/0001144204-17-065699-index.htm
2018-01-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418000340/0001144204-18-000340-index.htm
2018-01-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418001203/0001144204-18-001203-index.htm
2018-01-10SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418001565/0001144204-18-001565-index.htm
2018-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418008299/0001144204-18-008299-index.htm
2018-02-2820-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369868/000114420418011790/0001144204-18-011790-index.htm
2018-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418011834/0001144204-18-011834-index.htm
2018-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418021951/0001144204-18-021951-index.htm
2018-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418025437/0001144204-18-025437-index.htm
2018-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418025751/0001144204-18-025751-index.htm
2018-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418033660/0001144204-18-033660-index.htm
2018-06-18SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418034488/0001144204-18-034488-index.htm
2018-06-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418034717/0001144204-18-034717-index.htm
2018-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418036814/0001144204-18-036814-index.htm
2018-07-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418037609/0001144204-18-037609-index.htm
2018-07-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418038054/0001144204-18-038054-index.htm
2018-07-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418039751/0001144204-18-039751-index.htm
2018-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418041953/0001144204-18-041953-index.htm
2018-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418043731/0001144204-18-043731-index.htm
2018-08-20SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418045448/0001144204-18-045448-index.htm
2018-08-20SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418045449/0001144204-18-045449-index.htm
2018-08-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418045699/0001144204-18-045699-index.htm
2018-08-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418046156/0001144204-18-046156-index.htm
2018-08-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418046349/0001144204-18-046349-index.htm
2018-08-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418046354/0001144204-18-046354-index.htm
2018-08-27SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418046359/0001144204-18-046359-index.htm
2018-08-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418046753/0001144204-18-046753-index.htm
2018-09-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418047818/0001144204-18-047818-index.htm
2018-09-14SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418049406/0001144204-18-049406-index.htm
2018-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418050371/0001144204-18-050371-index.htm
2018-09-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418050458/0001144204-18-050458-index.htm
2018-10-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418053916/0001144204-18-053916-index.htm
2018-10-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418056273/0001144204-18-056273-index.htm
2018-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418056832/0001144204-18-056832-index.htm
2018-11-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420418060599/0001144204-18-060599-index.htm
2018-12-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420418064551/0001144204-18-064551-index.htm
2019-01-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419000779/0001144204-19-000779-index.htm
2019-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419004520/0001144204-19-004520-index.htm
2019-02-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419009113/0001144204-19-009113-index.htm
2019-02-208-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1369868/000114420419009120/0001144204-19-009120-index.htm
2019-03-0620-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1369868/000114420419012555/0001144204-19-012555-index.htm
2019-03-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419012588/0001144204-19-012588-index.htm
2019-05-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419025300/0001144204-19-025300-index.htm
2019-05-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419025309/0001144204-19-025309-index.htm
2019-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419026611/0001144204-19-026611-index.htm
2019-06-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419033066/0001144204-19-033066-index.htm
2019-08-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419037681/0001144204-19-037681-index.htm
2019-09-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419045132/0001144204-19-045132-index.htm
2019-09-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420419045140/0001144204-19-045140-index.htm
2019-09-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420419045144/0001144204-19-045144-index.htm
2019-09-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1369868/000114420419045332/0001144204-19-045332-index.htm
2019-09-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1369868/000114420419045691/0001144204-19-045691-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000142284818000281/0001422848-18-000281-index.htm
2018-11-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000142284818000410/0001422848-18-000410-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000142284819000029/0001422848-19-000029-index.htm
2019-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000142284819000137/0001422848-19-000137-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1369868/000142284819000143/0001422848-19-000143-index.htm